Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ("VIC") at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases -October 05, 2023 at 08:32 am EDT
JUPITER, Fla., Oct. 05, 2023 -- Dyadic International, Inc. , a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
United States Mark Emalfarb Mark Poznansky Patrickj Gallagher Voltron Therapeutics Inc Us Department Of Defense Do
Source: marketscreener.com